ADMA Biologics

174 articles about ADMA Biologics

• ADMA Biologics Reports First Quarter 2020 Financial Results and Highlights Recent Company Progress

  5/6/2020

  ADMA Biologics, Inc. reported financial results for the quarter ended March 31, 2020, ADMA’s first fiscal quarter, and provided an overview of recent progress and accomplishments.

• ADMA Biologics to Report First Quarter 2020 Financial Results on May 6, 2020Conference Call Scheduled for Wednesday, May 6, 2020, at 4:30 p.m. ET

  4/29/2020

  ADMA Biologics, Inc., an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and for the prevention of certain infectious diseases, announced that it will report financial results for the first quarter ended March 31, 2020 on Wednesday, May 6, 2020 after the U.S. financial markets close.

• ADMA Biologics Reports Fourth Quarter and Full Year 2019 Financial Results and Highlights Recent Company Progress

  3/12/2020

  ADMA Biologics, Inc. (NASDAQ: ADMA) (“ADMA”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and for the prevention of certain infectious diseases, today reported financial results for the fourth quarter and full year ended December 31, 2019 and provided an overview of recent progress and accomplishments.

• ADMA Biologics to Report Fourth Quarter and Full Year 2019 Financial Results on March 12, 2020Conference Call Scheduled for Thursday, March 12, 2020, at 4:30 p.m. ET

  3/5/2020

  ADMA Biologics, Inc. (NASDAQ: ADMA) (“ADMA”), today announced that it will report financial results for the fourth quarter and full year ending December 31, 2019 on Thursday, March 12, 2020 after the U.S. financial markets close

• ADMA Biologics Highlights Expanded Intellectual Property Portfolio for Specialty Plasma Derived Immune Globulins Targeted Against Respiratory Infections

  3/3/2020

  ADMA Biologics (“ADMA”), today announced that it has received another Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) for a patent application related to its intellectual property portfolio encompassing immunoglobulin plasma pool compositions used in the manufacturing of ASCENIV™

• ADMA Biologics Announces Closing of Full Exercise of Underwriters’ Option to Purchase Additional Shares in Connection with Its Public Offering of Common Stock

  2/24/2020

  ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA”), today announced the closing of the issuance of an additional 3,525,000 shares of its common stock at a public offering price of $3.50 per share

• ADMA Biologics Receives BioNJ 2020 Innovator Award for ASCENIV™

  2/11/2020

  ADMA Biologics, Inc. announced that it was awarded the BioNJ 2020 Innovator Award in recognition of the development and approval of ASCENIV™ by the U.S.

• ADMA Biologics Announces Pricing of Upsized $82.3 Million Public Offering of Common Stock

  2/7/2020

  ADMA Biologics, Inc. announced the pricing of its previously announced underwritten public offering of 23,500,000 shares of its common stock at a public offering price of $3.50 per share, resulting in gross proceeds of approximately $82.3 million before deducting underwriting discounts and commissions and other estimated offering expenses..

• ADMA Biologics Announces Proposed $75 Million Public Offering of Common Stock

  2/6/2020

  ADMA Biologics, Inc. an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases, announced that it has commenced an $75 million underwritten public offering of its common stock.

• ADMA Biologics Announces Preliminary Fourth Quarter and Full Year 2019 Revenues and Provides 2020 Strategic Outlook

  1/9/2020

  Achieved Fourth Quarter 2019 Preliminary Unaudited Total Revenues of $11.9 Million, a 193% Increase Over Fourth Quarter 2018

• ADMA Biologics Enters Into a Manufacturing and Supply Agreement to Produce and Sell Plasma-Derived Intermediate Fractions

  1/7/2020

  Agreement is Expected to Add $5-10 Million in Annual Revenues for 2020 and 2021, and $10-20 Million Per Year for 2022 Through 2024

• ADMA Biologics Added to NASDAQ Biotechnology Index

  12/17/2019

  ADMA Biologics, Inc. (NASDAQ: ADMA) (“ADMA” or the “Company”), a commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and the prevention of certain infectious diseases, today announced that it has been selected for addition to the NASDAQ Biotechnology Index® (NASDAQ: ^NBI)

• ADMA Biologics to Present at Jefferies 2019 London Healthcare Conference

  11/13/2019

  ADMA Biologics, Inc. announced that Adam Grossman, President and Chief Executive Officer, is scheduled to present a corporate overview at the Jefferies 2019 London Healthcare Conference, to be held November 20-21, 2019, at the Waldorf Hilton London, UK. ADMA is scheduled to present on Wednesday, November 20, 2019 at 8:00 AM GMT.

• ADMA Biologics Reports Third Quarter 2019 Financial Results and Highlights Recent Company Progress

  11/6/2019

  ADMA Biologics, Inc. announced financial results for the third quarter and nine months ended September 30, 2019, and provided an overview of its recent corporate achievements.

• ADMA Biologics Announces Acceptance to the Plasma Protein Therapeutics AssociationAdam Grossman, President & CEO, to Join PPTA North America Board of Directors

  11/4/2019

  ADMA Biologics, Inc. (NASDAQ: ADMA) (“ADMA” or the “Company”), a commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and the prevention of certain infectious diseases, today announced that it has been accepted as a member of the Plasma Protein Therapeutics Association (PPTA) as a North America Member effective January 1, 2020.

• ADMA Biologics Named Company of the Year by BioFlorida

  10/22/2019

  ADMA Biologics, Inc. announced that it has been named Company of the Year by BioFlorida, in recognition of ADMA’s significant achievements over the past year.

• ADMA Biologics Announces First Commercial Sales of ASCENIV™

  10/21/2019

  ADMA Biologics, Inc. (NASDAQ: ADMA) (“ADMA” or the “Company”), a commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and the prevention of certain infectious diseases, today announced the first commercial sales of ASCENIV (formerly known as RI-002).

• ADMA Biologics Announces Publication of an Article Describing the Manufacturing Process Optimization for its Commercial Products BIVIGAM® and ASCENIV™ in the Peer Reviewed Journal Immunotherapy

  10/17/2019

  ADMA Biologics, Inc. (NASDAQ: ADMA) (“ADMA” or the “Company”), today announced the publication of an article describing the manufacturing process optimization of ADMA’s Intravenous Immunoglobulin (“IVIG”) products, BIVIGAM® and ASCENIV

• 

  Clinical Catch-Up: October 7-11

  10/14/2019

  It was a busy week for clinical trial announcements. Here’s a look.
• 

  FDA Gives ADMA's Asceniv for Immune Deficiency the Thumbs-Up

  4/2/2019

  The U.S. Food and Drug Administration (FDA) approved ADMA Biologics’ Asceniv to treat Primary Humoral Immunodeficiency Disease (PIDD or PI) in adults and adolescents.